Physician profile
Gerardo Rodriguez
NPI 1346292620
$3,104.48
in general payments reported to CMS, 2019-2025
24 companies · $412 in 2025
The $412 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $100 · 2021: $512 · 2022: $898 · 2023: $332 · 2024: $513 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,210 · Education: $46.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,209.61 |
| Education | $46.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $407.22 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $339.30 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $336.30 | 2022-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $241.06 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $229.32 | 2022-2025 | Acthar, Terlivaz |
| Shockwave Medical, INC | $172.84 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $158.51 | 2019-2025 | Jynarque |
| Edwards Lifesciences Corporation | $153.50 | 2024 | Sapien 3 Ultra Resilia |
| Vifor Pharma, INC. | $139.13 | 2019-2021 | |
| Avinger INC. | $123.86 | 2021 | |
| Alexion Pharmaceuticals, INC. | $120.87 | 2019-2023 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $113.85 | 2022 | |
| Ardelyx, INC. | $103.03 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $89.83 | 2022 | |
| Amgen INC. | $89.12 | 2019-2025 | Krystexxa, Tavneos |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $74.15 | 2024 | Watchman Flx |
| Opko Pharmaceuticals, LLC | $33.32 | 2023-2025 | Rayaldee |
| Glaxosmithkline, LLC. | $31.95 | 2021 | |
| Novartis Pharmaceuticals Corporation | $30.79 | 2024 | |
| Lilly USA, LLC | $29.06 | 2023 | Jardiance |
| Aurinia Pharma U.S., INC. | $27.97 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.28 | 2023 | Jardiance |
| Fresenius USA Marketing, INC. | $18.89 | 2022 | |
| Scpharmaceuticals INC. | $17.33 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerardo Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.